CGNH CardioGenics Holdings Inc (CE)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

 Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): January 12, 2015

 

CardioGenics Holdings Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Nevada		000-28761		88-0380546
(State or other jurisdiction of incorporation)		(Commission  File Number)		(I.R.S. Employer Identification)

 

6295 Northam Drive, Unit 8, Mississauga, Ontario, L4V 1W8

(Address of Principal Executive Offices)(Zip Code)

 

Registrant’s telephone number, including area code: 905.673.8501

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

TABLE OF CONTENTS

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory	3
Item 7.01 Regulation FD Disclosure	3
Item 9.01 Exhibits	3
SIGNATURE	4

 

 

Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory

 

On January 12, 2015 the board of directors (the “Board”) of CardioGenics Holdings Inc. (the “Company”) appointed Karim Murabet as a director of the Company. Mr. Murabet will serve as an independent director of the Company.

 

Mr. Murabet has extensive business experience in diverse fields. He began his career as a professional soccer player around the world and went on to work in the sporting goods industry as the owner of Lanzera Italia. He also served as a football manager in various countries. As an investor, he is currently co-owner of Libyan Italian Real Estate Investment Co. and a consultant and advisor to Gruppo Bonifaci, one of Italy’s largest real estate developers based in Rome.

 

Mr. Murabet currently resides in the United Arab Emirates and is a Partner and Director responsible for business development and public relations in ICap Group FZC, a property development, architecture, hotel management and investment company registered in the United Arab Emirates.

 

Mr. Murabet is a graduate of College du leman in Versoix, Switzerland and received a BA in human behavior and later an MBA in business from U.S. International University-San Diego.

 

Item 7.01 – Regulation FD Disclosure

 

On January 12, 2015, the Company issued a press release reporting the appointment of Karim Murabet as a director of the Company. A copy of the press release is attached hereto as Exhibit 99.1.

 

The information in Exhibit 99.1 shall not be deemed as “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of such Section, nor shall it be deemed incorporated by reference in any filing by us under the Securities Act, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.

 

Item 9.01 Exhibits.

 

(d) Exhibits

  

99.1	Press Release dated January 12, 2015.

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

	CARDIOGENICS HOLDINGS INC.
	By:	/s/ Yahia Gawad
	Name:	Yahia Gawad
	Title:	Chief Executive Officer

  

Dated: January 12, 2015

 

   

 

 

EXHIBIT 99.1

  

 

 

CardioGenics Announces Appointment of New Director

 

MISSISSAUGA, Ontario – January 12, 2015 – CardioGenics Holdings Inc. (OTCQB: CGNH), developer of the ultra-sensitive QL Care™ analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics testing market, announced today that Karim Murabet has been appointed as a director of the Company, effective January 12, 2015. Mr. Murabet will serve as an independent director.

 

Dr. Yahia Gawad, Chief Executive Officer of CardioGenics, commented, “We are extremely pleased to have an individual of Karim’s reputation and experience joining CardioGenics. Karim brings a strong background in international business that will enhance the expertise, knowledge and skills of our board. We look forward to working with Karim as we move forward with the commercialization of our products and our growth strategy.”

 

Mr. Murabet has extensive business experience in diverse fields. He began his career as a professional soccer player around the world and went on to work in the sporting goods industry as the owner of Lanzera Italia. His passion for sports also led him to be a football manager in various countries. As an investor, he is currently co-owner of Libyan Italian Real Estate Investment Co. and a consultant and advisor to Gruppo Bonifaci, one of Italy’s largest real estate developers, based in Rome.

 

Mr. Murabet currently resides in the United Arab Emirates and is a Partner and Director responsible for business development and public relations in ICap Group FZC, a property development, architecture, hotel management and investment company registered in the United Arab Emirates.

 

Mr. Murabet is a graduate of College du leman in Versoix, Switzerland and received a BA in human behavior and later an MBA in business from U.S. International University-San Diego.

 

 

ABOUT CARDIOGENICS HOLDINGS INC.

 

Through its operating subsidiaries, the Company develops ultra-sensitive analyzers and other products targeting the immunoassay segment of the IVD testing market. It has developed the QL Care™ Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental component of immunoassay equipment), which improve instrument sensitivity to light. The Company’s proprietary microspheres technology and SAVAsphere™ magnetic beads are developed and marketed through the Company’s Luxspheres subsidiary. The Company’s principal offices are located in Mississauga, Ontario, Canada. For more information please visit www.cardiogenics.com and www.luxspheres.com.

 

Safe Harbor Statement - Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as “anticipate, “believe,” “expect,” “future,” “may,” “will,” “should,” “plan,” “projected,” “intend,” and similar expressions to identify forward-looking statements. These statements are based on the Company’s beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company’s current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company’s periodic filings with the Securities and Exchange Commission.

  

For more information about CardioGenics:

 

CardioGenics Holdings Inc.

Joseph J. Nese

Tel: 1.516.428.4200